- Home
- KLTO vs HOTH Comparison
KLTO vs HOTH Comparison
Compare KLTO & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTO
- HOTH
- Stock Information
- Founded
- KLTO 2019
- HOTH 2017
- Country
- KLTO United States
- HOTH United States
- Employees
- KLTO N/A
- HOTH N/A
- Industry
- KLTO
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- KLTO
- HOTH Health Care
- Exchange
- KLTO NYSE
- HOTH Nasdaq
- Market Cap
- KLTO 9.8M
- HOTH 8.3M
- IPO Year
- KLTO N/A
- HOTH 2019
- Fundamental
- Price
- KLTO $0.38
- HOTH $1.06
- Analyst Decision
- KLTO
- HOTH Strong Buy
- Analyst Count
- KLTO 0
- HOTH 4
- Target Price
- KLTO N/A
- HOTH $4.75
- AVG Volume (30 Days)
- KLTO 185.8K
- HOTH 673.3K
- Earning Date
- KLTO 03-04-2025
- HOTH 03-27-2025
- Dividend Yield
- KLTO N/A
- HOTH N/A
- EPS Growth
- KLTO N/A
- HOTH N/A
- EPS
- KLTO N/A
- HOTH N/A
- Revenue
- KLTO N/A
- HOTH N/A
- Revenue This Year
- KLTO N/A
- HOTH N/A
- Revenue Next Year
- KLTO N/A
- HOTH N/A
- P/E Ratio
- KLTO N/A
- HOTH N/A
- Revenue Growth
- KLTO N/A
- HOTH N/A
- 52 Week Low
- KLTO $0.26
- HOTH $0.58
- 52 Week High
- KLTO $13.10
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- KLTO N/A
- HOTH 42.86
- Support Level
- KLTO N/A
- HOTH $1.01
- Resistance Level
- KLTO N/A
- HOTH $1.09
- Average True Range (ATR)
- KLTO 0.00
- HOTH 0.08
- MACD
- KLTO 0.00
- HOTH -0.02
- Stochastic Oscillator
- KLTO 0.00
- HOTH 25.93
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.